开幕式上同步举行两项重要仪式：创新药械技术引进专家委员会筹备启动仪式正式启动，将汇聚各 领域权威院士专家，推动创新药械引进决策科学化、临床需求对接精准化;"创新之光"药械颁奖仪式同 期举办，对一批具有代表性的创新产品和合作机构进行了表彰，大会还设立了"先行先试"突破创新奖等 多个奖项，对在医疗创新领域取得突出成果的相关主体予以表彰，激励产业链上下游的各方伙伴继续深 化合作。 本次博览会汇聚全球医疗创新智慧，集中发布100余款国际创新药械、特医食品及生物医学新技 术，权威发布《海南博鳌乐城国际医疗旅游先行区国际创新药械引进及使用白皮书》。此外，博览会还 助力搭建"政企研"精准对接平台，为全球医疗健康产业注入新动能。 海南日报博鳌11月21日电(海南日报全媒体见习记者 陈美如)11月21日，海南博鳌乐城首届全球创 新药械博览会在乐城先行区开幕。 本届博览会以"智汇全球创新技术，共筑人类健康未来"为主题，汇聚了国内外政府代表、医疗机 构、科研院所、高校专家及企业代表约700人，旨在搭建全球医疗科技交流合作平台，开展全球创新药 械及医疗技术研发趋势与临床应用研讨活动，深化药械研发、生产、流通全链条协同合作，推动国际前 ...

据了解，《白皮书》收集了乐城先行区引进使用的全球创新性强的药械产品、特医食品、保健食品 及生物医学新技术项目共100余款，并摘录了部分患者在乐城先行区接受临床治疗或使用相关产品的真 实案例，生动呈现了其在疗效改善与生活质量提升等方面的切实获益。同时，《白皮书》以六大核心板 块为框架，从国际药械获批、特许引进、乐城患者使用特许药械产品治疗效果案例、真实世界数据应 用，到本地化生产与未来引进计划，系统地阐述了乐城在医疗创新领域的实践路径，全方位勾勒出乐城 作为中国医疗创新试验田和窗口的独特价值。 海南日报博鳌11月21日电(海南日报全媒体见习记者 陈美如)11月21日，海南博鳌乐城首届全球创 新药械博览会在乐城国际医疗旅游先行区举行。备受瞩目的行业指南《海南博鳌乐城国际医疗旅游先行 区国际创新药械引进及使用白皮书》(以下简称《白皮书》)首次权威发布。 ...

成立合资公司旨在充分利用海南博鳌乐城国际医疗旅游先行区相关特许政策，包括但不限于"国九条"框 架下的临床急需进口器械的快速审批通道、真实世界数据应用试点以及境外医师执业便利化等政策优 势，从而实现国际创新医疗（002173）器械在中国境内的快速注册、临床应用及商业化落地。通过与先 行区管理机构、医疗机构及行业伙伴的合作，合资公司将构建一个集政策对接、技术转化与临床验证于 一体的协同平台，进一步加快全球前沿医疗技术在中国的准入进程，提升创新成果的临床转化效率及商 业价值。公司认为，此次合作符合国家鼓励医疗创新及高水平对外开放的战略方向，有助于丰富本公司 医疗器械业务管线，并为股东创造长期价值。 环球医疗(02666)发布公告，于2025年11月18日(交易时段后)，公司、中机新能(通用技术集团间接全资 附属公司)及和乐科技签署成立合资公司的协议。根据协议规定，合资公司的注册资本为人民币3000万 元，由相关各方以现金形式出资，其中：(i)公司出资人民币1503万元，(ii)中机新能出资人民币447万 元，及(iii)和乐科技出资人民币1050万元。合资公司成立后，其注册资本将由公司、中机新能及和乐科 技分别持有 ...

Group 1 - The core point of the news is the establishment of a joint venture between Universal Medical (02666), China National Machinery New Energy, and HeLe Technology, with a registered capital of RMB 30 million [1][2] - Universal Medical will contribute RMB 15.03 million, China National Machinery New Energy will contribute RMB 4.47 million, and HeLe Technology will contribute RMB 10.5 million, resulting in ownership stakes of 50.1%, 14.9%, and 35% respectively [1][2] - The joint venture aims to leverage the preferential policies of the Boao Lecheng International Medical Tourism Pilot Zone, facilitating rapid approval and commercialization of innovative medical devices in China [2] Group 2 - The collaboration is expected to create a platform for policy alignment, technology transfer, and clinical validation, enhancing the efficiency and commercial value of innovative medical technologies in China [2] - This initiative aligns with national strategies to encourage medical innovation and high-level openness, enriching the company's medical device pipeline and creating long-term value for shareholders [2]

Core Viewpoint - The healthcare industry is facing the challenge of innovating across multiple fields to address service pain points and promote high-quality development in public hospitals, as emphasized by the director of Nanshan People's Hospital in Shenzhen [1] Group 1: Smart Hospital Construction - The "Action for Promoting High-Quality Development of Public Hospitals" highlights the construction of a "three-in-one smart hospital" as a key task for digital transformation [2] - Nanshan People's Hospital focuses on four key areas: innovation, intelligence, service, and safety, to build a regional characteristic smart medical system [2] - The hospital leverages local technological advantages to collaborate with universities on AI-assisted diagnosis and smart surgical robots, integrating over 20 internal systems to create a comprehensive health database [2] Group 2: Technology Empowerment in Healthcare - Technological innovation is identified as the core driving force for high-quality development in public hospitals [3] - The hospital aims to enhance clinical demand-driven technology implementation, improving diagnostic accuracy from 85% to 97%-98% with AI systems [3] - A closed-loop system is established to connect clinical needs, research, and application, optimizing patient wait times to under 30 minutes through online processes [3] Group 3: Enhancing Patient Experience - Patient experience is a critical measure of high-quality development, with the hospital focusing on emotional satisfaction alongside functional needs [4] - Initiatives include a one-stop service center in the outpatient hall and a follow-up mechanism using smart devices to track patient health data, achieving a patient satisfaction rate of 96.8% [4] - The hospital has implemented a dual-driven system of "institution + ecology" to ensure long-term patient experience improvements, linking performance metrics to staff evaluations [5]

Core Insights - The healthcare innovation sector is showing positive momentum, with the China Securities Medicine and Medical Device Innovation Index (931484) rising by 0.31% as of November 14, 2025, and several key stocks, including Sanofi and Ganli Pharmaceutical, experiencing significant gains [1] Group 1: Market Performance - The China Securities Medicine and Medical Device Innovation Index has seen a 0.31% increase, with notable stock performances: Sanofi up 4.64%, Ganli Pharmaceutical up 3.28%, and Jiutian Pharmaceutical up 1.83% [1] - The Medical Innovation ETF (516820) has also risen by 0.26%, marking its third consecutive increase [1] Group 2: Clinical Developments - AstraZeneca announced successful Phase III clinical trials for Baxdrostat, which significantly reduced 24-hour average systolic blood pressure in patients with resistant hypertension over 12 weeks, indicating a new treatment pathway for hypertension [1] Group 3: Industry Trends - According to Dongfang Caifu Securities, the pharmaceutical industry showed improvement in Q3 2025, with the medical device sector experiencing a turning point, achieving positive year-on-year revenue growth and a notable narrowing of net profit declines [1] - The CXO sector performed exceptionally well in the first three quarters of 2025, with medical R&D outsourcing revenue increasing by 12.2% and net profit rising by 56.8%, particularly in ADC CDMO and peptide CDMO fields [2] - The index reflects the performance of 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors, with the top ten stocks accounting for 64.12% of the index [2]

此外，圆桌对话也探讨了技术创新与医学教育相融合的话题，例如让科研人员接触临床实践以培养转化 思维，走到临床中心的第一线去理解临床管理；以及开展高质量的多中心临床试验对于收集循证医学证 据、助力创新产品走向全球的重要性。在对话中，与会专家也呼吁，要重视跨学科、跨专业的协作，以 完成安全、高质量的研究；要用"登月"一般的雄心与愿景，共同推动创新。这场思想盛宴所碰撞出来的 智慧火花，为中国的医疗创新人才指明了前进方向。 围绕破解"全球技术落地难、本土创新转化慢"的问题，张珺表示，波士顿科学对中国的定位，早已超越 单纯的供应商或销售市场，而是将中国视为解决未来全球医疗健康问题大网络中的一块重要创新高地。 我们希望通过整合本土优质资源，更好地服务中国医患，这也清晰地体现在波士顿科学在华发展的三个 阶段：从本土智造，到深耕研发，再到共创医疗生态。展望未来，波士顿科学希望不仅是一个品牌，更 是深度融入中国医疗体系、充满活力的共建者。 谈及进入国内心血管医疗器械创新市场所遇到的难点，张珺也分享了当前医疗器械创新面临两大核心挑 战。一是创新转化之难。医疗器械创新涵盖材料、工程与临床等众多学科，是一项复杂的体系工程，打 通跨学科 ...

Core Insights - The China International Import Expo (CIIE) has established a medical innovation incubation zone that serves as a testing ground for innovative small and micro enterprises, facilitating the connection between domestic demand and high-quality international resources, thus promoting domestic industrial innovation and transformation [1][4] Group 1: Innovations in Medical Technology - The medical innovation incubation zone showcases various innovative technologies, including emergency testing equipment suitable for small spaces, inhalation powder aerosols that reduce gastrointestinal side effects, and non-invasive balloons to decrease food intake [1] - Weide Precision's intelligent surgical robot, which integrates with CT imaging systems, enhances the precision and efficiency of percutaneous interventions by intelligently planning puncture paths and achieving real-time data fusion [1][3] Group 2: Market Trends and Collaborations - A notable trend is the increasing emphasis on "reverse driving global technology redesign" based on Chinese market demands, indicating that China's medical innovation landscape is becoming a source for transforming concepts into real applications [2][3] - Weide Precision aims to establish connections with domestic clinical partners and multinational companies, positioning itself as an ecosystem enterprise within the medical technology sector [2] Group 3: Local Innovation and Global Integration - The rapid growth of local innovation in the in vitro diagnostics field is highlighted, with companies like Kuaosen Duo establishing R&D centers in China to adapt global innovations to local clinical needs [3] - The "Medical Innovation · China Landing" project selection mechanism has begun to show platform effects, with numerous high-potential medical products from over ten countries being showcased, representing cutting-edge medical technology trends [3] Group 4: Global Health Needs and Collaborative Platforms - The Wanjiang International Medical Innovation Forum, part of the CIIE, aims to address unmet global health needs by creating a platform for efficient collaboration and technology transfer in China [4][5] - The medical innovation incubation zone is evolving into a source, accelerator, and driving point for innovation elements in China, enhancing the feasibility of project conversion from display to market application [5]

Core Points - The 8th China International Import Expo (CIIE) has commenced, with Roche Pharmaceuticals participating for the eighth consecutive year, showcasing over 40 products and innovative solutions under the theme "Leading Innovation, Safeguarding Life" [1][2][7] - Roche is presenting more than ten products that will soon be launched in China, marking a historic high for the company, including the anti-CD20 monoclonal antibody, Gazyva® (obinutuzumab), and the Port Delivery System (PDS) for ophthalmology [1][12] - Roche's new biopharmaceutical production base, with an investment of 2.04 billion RMB, is a significant milestone in its localization strategy in China, reinforcing its commitment to the market as it approaches its 100th anniversary in the country [8][19] Company Overview - Roche has established itself as a leader in the biopharmaceutical industry, transitioning from a specialist in oncology and specialty drugs to a comprehensive leader across all disease areas [12][19] - The company is showcasing a wide array of products across various therapeutic areas, including Alzheimer's, Parkinson's, hypertension, and metabolic diseases, with several pipeline products in large-scale Phase III clinical trials [12][19] - Roche's innovative drug delivery methods, such as the PDS, represent a significant advancement in patient care, allowing for sustained drug release and reducing the need for frequent injections [15][19] Industry Context - The CIIE serves as a crucial platform for global cooperation and market openness, facilitating dialogue between foreign enterprises like Roche and the Chinese government [10][11] - The ongoing improvement of China's business environment and innovation ecosystem provides fertile ground for foreign investment, as evidenced by Roche's substantial investment in local production capabilities [8][19] - Roche's participation in the CIIE highlights the importance of international collaboration in the life sciences sector, particularly in the context of the 75th anniversary of diplomatic relations between China and Switzerland [11][12]

第八届中国国际进口博览会医疗器械及医药保健展区迎来众多全球尖端医疗企业的前沿创新成果。记者 注意到，医疗器械展区最亮眼的关键词是"首发首秀"，全球最快CT机、骨科机器人新增脊椎手术和骨 折创伤手术等尖端医疗装备纷纷亮相。此外，一批通过进博会加速获批上市的创新药也成焦点，未来五 年，企业将在中国引进40个创新产品和适应证。进博会为医疗企业提供了交流合作的平台，也展现了中 国持续扩大开放带来的发展机遇。（央视新闻） ...